/index.html View the latest �鶹������ Co., Ltd. news releases. /news/2026/news202621.html �鶹������'s news release Application Submitted for LENVIMA® (lenvatinib) in Japan Seeking Approval of Additional Dosage and Administration for Combination with WELIREG® (belzutifan) for Renal Cell Carcinoma that has Progressed After Chemotherapy is posted. 2026-03-27T10:00:00+09:00 /news/2026/news202620.html �鶹������'s news release �鶹������ and Nuvation Bio Announce Marketing Authorisation Application for Taletrectinib for the Treatment of Advanced ROS1-Positive Non-Small Cell Lung Cancer Validated by the European Medicines Agency is posted. 2026-03-27T08:00:00+09:00 /news/2026/news202618.html �鶹������'s news release Notice of Nominees for Directors is posted. 2026-03-26T17:00:00+09:00 /news/2026/news202616.html �鶹������'s news release Results from Real-World, Long-Term Treatment Persistence with LEQEMBI® (lecanemab-irmb) in the United States Presented at AD/PD™ 2026 is posted. 2026-03-23T08:30:00+09:00 /news/2026/news202615.html �鶹������'s news release Regarding Discontinuation of Administration of “Tazverik® Tablets 200mg” (tazemetostat hydrobromide) is posted. 2026-03-19T07:30:00+09:00 /news/2026/news202614.html �鶹������'s news release �鶹������ Established the Global Capability Centre in Visakhapatnam, India, to Standardize Global IT Infrastructure Operations and Digital Transformation is posted. 2026-03-17T16:45:00+09:00 /news/2026/news202613.html �鶹������'s news release Have Fun Exploring Sleep with Pokémon! �鶹������ Launches Awareness Campaign on Importance of Sleep Through "Pokémon Sleep" Collaboration is posted. 2026-03-12T12:00:00+09:00 /news/2026/news202612.html �鶹������'s news release �鶹������ to Present the Latest Data on Long-Term, Real-World Treatment with Lecanemab at the AD/PD™ 2026 Annual Meeting is posted. 2026-03-11T08:30:00+09:00 /news/2026/news202611.html �鶹������'s news release WELIREG® (belzutifan) Plus LENVIMA® (lenvatinib) Reduced the Risk of Disease Progression or Death by 30% Compared to Cabozantinib in Certain Previously Treated Patients With Advanced Renal Cell Carcinoma (RCC) is posted. 2026-03-02T08:30:00+09:00 /news/2026/news202610.html �鶹������'s news release Ministry of Health, Labour and Welfare Grants Orphan Drug Designation in Japan to Novel Orexin Receptor Agonist E2086 for Narcolepsy is posted. 2026-02-16T14:30:00+09:00 /news/2026/news202609.html �鶹������'s news release �鶹������ Announces Appointment of Corporate Officers is posted. 2026-02-09T15:30:00+09:00 /news/2026/news202608.html �鶹������'s news release Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Designated for Priority Review in China is posted. 2026-02-09T11:00:00+09:00 /news/2026/news202607.html �鶹������'s news release Revenue of LEQEMBI® (Preliminary Basis) is posted. 2026-02-06T20:00:00+09:00 /news/2026/news202606.html �鶹������'s news release �鶹������ and Henlius Enter into Exclusive Commercial License Agreement for Anti-PD-1 Antibody Serplulimab in Japan is posted. 2026-02-05T18:30:00+09:00 /news/2026/news202605.html �鶹������'s news release FDA Accepts LEQEMBI® IQLIK™ (lecanemab-irmb) Supplemental Biologics License Application as a Subcutaneous Starting Dose for the Treatment of Early Alzheimer’s Disease under priority Review is posted. 2026-01-26T08:30:00+09:00